Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cue Biopharma, Inc. (CUE) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company (Commission File Number 001-38327), Cue Biopharma uses SEC reports to communicate financial results, material agreements, leadership changes and other significant corporate events.
Investors researching CUE stock can review Form 10-K annual reports and Form 10-Q quarterly reports for detailed information on collaboration revenue, research and development spending, general and administrative expenses, cash and marketable securities, and risk factors related to the development of its Immuno-STAT® platform and pipeline candidates such as CUE-101, CUE-102, CUE-401 and CUE-501.
Form 8-K current reports are particularly relevant for Cue Biopharma, as they document material events including collaboration and license agreements, public offerings under its Form S-3 shelf registration statement, changes in executive leadership, facility lease amendments and key licensing transactions like the collaboration with ImmunoScape for the CUE-100 series. These filings often reference press releases furnished as exhibits, providing additional context on clinical and business developments.
This page also helps users locate information related to equity compensation and executive arrangements, which are described in employment agreements and separation agreements disclosed in 8-K filings. While Cue Biopharma’s insider transactions would appear in Form 4 filings submitted by individual officers and directors, aggregating these documents alongside periodic reports offers a fuller picture of governance and ownership activity.
Stock Titan enhances access to Cue Biopharma’s SEC filings with AI-powered summaries that explain key points from lengthy documents, highlight notable changes from prior periods and surface items that may be important to shareholders. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K and related forms are available promptly, helping users navigate the regulatory record behind CUE stock.
Cue Biopharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 13, 2026. The company explains how stockholders can submit proposals or director nominations for that meeting and the deadlines that apply.
Stockholder proposals intended for inclusion in the company’s proxy materials under SEC Rule 14a-8 must be received at Cue Biopharma’s Boston headquarters by February 28, 2026, which the company considers a reasonable time before it begins printing and mailing proxy materials. For other business or director nominations to be brought directly before the meeting under the company’s Amended and Restated Bylaws, notice must also be received by February 28, 2026, or the later of 90 days before the meeting and 10 days after public announcement of the meeting date.
The company notes that stockholders who plan to solicit proxies in favor of their own director nominees, rather than the company’s nominees, and who seek to comply with the SEC’s universal proxy rule (Rule 14a-19), must likewise provide the required notice by February 28, 2026. If a stockholder misses these deadlines, the board’s named proxies may exercise discretionary voting authority on that stockholder’s proposal at the 2026 Annual Meeting.
Cue Biopharma appointed Lucinda WarrenChief Financial and Business Officer
Warren has over 30 years of global experience in pharmaceuticals and biotechnology, including a decade in business development roles at Johnson & Johnson and leadership positions at Janssen organizations. She receives no additional compensation for these new responsibilities, her employment terms remain unchanged, and there are no related-party or family relationships tied to her appointment.
Cue Biopharma director Peter A. Kiener reported a new stock option grant dated 01/02/2026. He received a stock option for 24,400 shares of Cue Biopharma common stock with an exercise price of $0.34 per share, recorded as an acquisition of derivative securities. The option was granted under the company’s Director Compensation Policy and is scheduled to become fully exercisable on the first anniversary of the grant date, with an expiration date of 01/01/2036. Following this grant, Kiener beneficially owns 24,400 stock options directly.
Cue Biopharma, Inc. reported a routine insider transaction showing a stock option grant to director Pamela Garzone. On 01/02/2026, she received 24,400 stock options with an exercise price of $0.34 per share. According to the disclosure, the award was granted under the company’s Director Compensation Policy.
The filing states that this stock option becomes fully exercisable on the first anniversary of the grant date and carries an expiration date of 01/01/2036. Following this grant, Garzone beneficially owns 24,400 derivative securities directly, reflecting only this option award.
Cue Biopharma director Sarraf Pasha reported receiving a stock option award from the company. On 01/02/2026, Pasha was granted an option to buy 24,400 shares of Cue Biopharma common stock at an exercise price of $0.34 per share, with no cash paid for the grant itself. The award was made under the company’s Director Compensation Policy.
The filing states that this option becomes fully exercisable on the first anniversary of the grant date and carries an expiration date of 01/01/2036. Following this grant, Pasha beneficially owns 24,400 derivative securities in the form of these stock options, held directly.
Cue Biopharma is conducting a public offering of common stock, pre‑funded warrants and common stock warrants, all sold together as units. The pre‑funded warrants have a de minimis exercise price and are exercisable on a cashless basis, while the common stock warrants are exercisable for five years and may be cashless if no effective registration is available.
The company is a clinical‑stage biopharmaceutical developer using its Immuno‑STAT platform to target disease‑specific T cells in autoimmune diseases. As of September 30, 2025, it held $18.7 million in cash, cash equivalents and marketable securities and has a collaboration providing a $5.0 million upfront payment and a further $5.0 million time‑based payment due in December 2025, which together are expected to fund operations into the third quarter of 2026. Management states there is substantial doubt about the company’s ability to continue as a going concern and that proceeds from this offering will not be sufficient to remove that doubt, and notes that additional equity financing is likely to be dilutive.
Cue Biopharma, Inc. (CUE) reported a Form 4 transaction for its Chief Business Officer. The officer received a stock option grant covering 125,000 shares of Cue Biopharma common stock on 09/29/2025. The option has an exercise price of $0.72 per share and expires on 09/28/2035.
According to the filing, this stock option becomes fully exercisable on the first anniversary of the grant date, meaning the officer must wait one year before the option is fully vested. Following this grant, the officer beneficially owns 125,000 derivative securities, held directly. This transaction reflects equity-based compensation designed to align the officer’s interests with those of shareholders.
Cue Biopharma, Inc. (CUE) reported an equity award to its chief development officer. The reporting person received a stock option covering 50,000 shares of common stock at an exercise price of $0.72 per share on 09/29/2025. This option is scheduled to become fully exercisable on the first anniversary of the grant date and carries an expiration date of 09/28/2035. After this grant, the reporting person holds 50,000 derivative securities related to Cue Biopharma common stock with direct ownership.
Cue Biopharma, Inc. reported that on November 24, 2025 it made an updated corporate presentation publicly available on its website and furnished that presentation as Exhibit 99.1 to a Form 8-K. The company notes that the materials provided under Item 7.01, including the presentation, are being furnished rather than filed under the Exchange Act, which means they are not subject to certain liabilities associated with filed reports and are not automatically incorporated into other securities filings unless specifically referenced.
Cue Biopharma, Inc. (CUE) announced that Chief Medical Officer Matteo Levisetti will leave the company, with his employment ending on November 28, 2025. The company and Dr. Levisetti agreed to his separation on November 17, 2025.
Subject to signing and not revoking a separation and release of claims agreement, Dr. Levisetti will receive a lump-sum cash severance of $556,837.60, equal to nine months of base salary plus a prorated portion of his 2025 target bonus, paid in the first regular payroll cycle after the separation agreement becomes effective. If he elects COBRA coverage, Cue Biopharma will pay the full premiums for up to nine months after the Separation Date, or until he secures reasonably comparable new coverage or COBRA otherwise ends.